Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.

ABSTRACT: Recurrence score (RS) could be used to predict clinical outcomes and chemotherapy efficacy in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node-negative breast cancer. However, the clinical features and management of patients with an RS of 26-30 are not completely understood. In the present study, 783 patients with HR⁺/HER2^-, lymph node-negative early breast cancer and RS ≥18 were included and categorized into RS=18-25 (47.8%), 26-30 (25.5%) or ≥31 (26.7%) groups. Clinicopathological characteristics, adjuvant chemotherapy usage and disease outcomes were compared. Alterations in the adjuvant chemotherapy recommendation after 21-gene RS testing were also analyzed. The results indicated that patients wit

SUBMITTER: Yu J 

PROVIDER: S-EPMC7377026 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature